Compérat E, Camparo P. Histological classification of malignant renal tumours at a time of major diagnostic and therapeutic changes. Diagn Interv Imaging. 2012;93:221–31.
Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.
Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma. J Urol. 2009;181:2033–6.
Patel MI, Simmons R, Kattan MW, et al. Long-term follow-up of bilateral sporadic renal tumors. Urology. 2003;61:921–5.
Richstone L, Scherr DS, Reuter VR, et al. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol. 2004;171:615–20.
Zirinsky K, Auh YH, Rubenstein WA, et al. CT of the hyperdense renal cyst: sonographic correlation. AJR Am J Roentgenol. 1984;143:151–6.
Forman HP, Middleton WD, Melson GL, et al. Hyperechoic renal cell carcinomas: increase in detection at US. Radiology. 1993;188:431–4.
Press GA, McClennan BL, Melson GL, et al. Papillary renal cell carcinoma: CT and sonographic evaluation. AJR Am J Roentgenol. 1984;143:1005–9.
Hartman DS, David CJ Jr, Goldman SM, et al. Renal lymphoma: radiologic-pathologic correlation of 21 cases. Radiology. 1982;144:759–66.
Markic D, Krpina K, Ahel J, Spanjol J, Grskovic A, Stifter S, et al. Different presentations of renal cell cancer on ultrasound and computerized tomography. Urologia. 2014;81:228–32.
Wang C, Yu C, Yang F, Yang G. Diagnostic accuracy of contrast- enhanced ultrasound for renal cell carcinoma: a meta-analysis. Tumour Biol. 2014;35:6343–50.
Onur MR, Poyraz AK, Bozgeyik Z, Onur AR, Orhan I. Utility of semiquantitative strain elastography for differentiation between benign and malignant solid renal masses. J Ultrasound Med. 2015;34:639–47.
Habboub HK, Abu-Yousef MM, Williams RD, See WA, Schweiger GD. Accuracy of color Doppler sonography in assessing venous thrombus extension in renal cell carcinoma. Am J Roentgenol. 1997;168:267–71.
Hricak H, Thoeni RF, Carroll PR, Demas BE, Marotti M, Tanagho EA. Detection and staging of renal neoplasms: a reassessment of MR imaging. Radiology. 1988;166:643–9.
Roubidoux MA, Dunnick NR, Sostman HD, Leder RA. Renal carcinoma: detection of venous extension with gradient-echo MR imaging. Radiology. 1992;182:269–72.
Jamis-Dow CA, Choyke PL, Jennings SB, et al. Small (< or 5 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology. 1996;198:785–8.
Bhosale PR, Wei W, Ernst RD, Bathala TK, Reading RM, Wood CG, et al. Intraoperative sonography during open partial nephrectomy for renal cell cancer: does it alter surgical management. Am J Roentgenol. 2014;203:822–7.
Zhang J, Lefkowitz RA, Bach A. Imaging of kidney cancer. Radiol Clin North Am. 2007;45:119–47.
Sankineni S, Brown A, Cieciera M, Choyke PL, Turkbey B. Imaging of renal cell carcinoma. Urol Oncol. 2016;34:147–55.
Kang SK, Kim D, Chandarana H. Contemporary imaging of the renal mass. Curr Urol Rep. 2011;12:11–7.
Hélénon O, Eiss D, Debrito P, Merran S, Correas JM. How to characterise a solid renal mass: a new classification proposal for a simplified approach. Diagn Interv Imaging. 2012;93:232–45.
Zhang J, Lefkowitz RA, Ishill NM, et al. Solid renal cortical tumors: differentiation with CT. Radiology. 2007;244:494–504.
Herts BR, Coll DM, Novick AC, et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol. 2002;178:367–72.
Couvidat C, Eiss D, Merran S, Vieillefond A, Correas JM, Hélénon O. Papillary renal cell carcinoma: spectrum of imaging findings with pathologic correlation. Chicago, United States, RSNA annual meeting; 2008 30th November–5th December.
Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. 2004;231:365–71.
Abdulla C, Kalra MK, Saini S, et al. Pseudoenhancement of simulated renal cysts in a phantom using different multidetector CT scanners. AJR Am J Roentgenol. 2002;179:1473–6.
Lesavre A, Correas JM, Merran S, Grenier N, Vieillefond A, Hélénon O. CT of papillary renal cell carcinoma with cholesterol necrosis mimicking angiomyolipomas. AJR Am J Roentgenol. 2003;181:143–5.
Kallman DA, King BF, Hattery RR, Charboneau JW, Ehman RL, Guthman DA, et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr. 1992;16:240–7.
Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. Eur Urol. 2011;60:241–8.
Karçaaltıncaba M, Aktaş A. Dual-energy CT revisited with multidetector CT: review of principles and clinical applications. Diagn Interv Radiol. 2011;17:181–94.
Graser A, Becker CR, Staehler M, et al. Single phase dual-energy CT allows for characterization of renal masses as benign or malignant. Invest Radiol. 2010;45:399–405.
Mileto A, Nelson RC, Paulson EK, Marin D. Dual-Energy MDCT for Imaging the Renal Mass. AJR Am J Roentgenol. 2015;204:W640–7.
Pretorius ES, Wickstrom ML, Siegelman ES. MR imaging of renal neoplasms. Magn Reson Imaging Clin N Am. 2000;8:813–36.
Willatt JM, Hussain HK, Chong S, Kappil M, Azar SF, Liu PS, et al. MR imaging in the characterization of small renal masses. Abdom Imaging. 2014;39:761–9.
Taouli B, Thakur RK, Mannelli L, Babb JS, Kim S, Hecht EM, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251:398–407.
Wang H, Cheng L, Zhang X, Wang D, Guo A, Gao Y, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology. 2010;257:135–43.
Sasiwimonphan K, Takahashi N, Leibovich BC, Carter RE, Atwell TD, Kawashima A. Small (< 4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology. 2012;263:160–8.
Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, et al. Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. Radiology. 2012;265:799–808.
Wagstaff PG, Zondervan PJ, de la Rosette JJ, Laguna MP. The role of imaging in the active surveillance of small renal masses. Curr Urol Rep. 2014;15:386.
Min JH, Kim CK, Park BK, Kim E, Kim B. Assessment of renal lesions with blood oxygenation level-dependent MRI at 3T:preliminary experience. Am J Roentgenol. 2011;197:W489–94.
Rha SE, Byun JY, Jung SE, et al. The renal sinus: pathologic spectrum and multimodality imaging approach. Radiographics. 2004;24:S117–31.
Urban BA, Buckley J, Soyer P, et al. CT appearance of transitional cell carcinoma of the renal pelvis: Part 1. early-stage disease. AJR Am J Roentgenol. 1997;169:157–61.
Browne RF, Meehan CP, Colville J, et al. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics. 2005;25:1609–27.
Urban BA, Buckley J, Soyer P, et al. CT appearance of transitional cell carcinoma of the renal pelvis: Part 2. advanced-stage disease. AJR Am J Roentgenol. 1997;169:163–8.
Curry NS. Small renal masses (lesions smaller than 3 cm): imaging evaluation and management. AJR Am J Roentgenol. 1995;164:355–62.
Israel GM, Krinsky GA. MR imaging of the kidneys and adrenal glands. Radiol Clin North Am. 2003;41:145–59.
Cohan RH, Dunnick NR, Leder RA, et al. Computed tomography of renal lymphoma. J Comput Assist Tomogr. 1990;14:933–8.
Johnson CD, Dunnick NR, Cohan RH, et al. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol. 1987;148:59–63.
Roy C Sr, El Ghali S, Buy X, et al. Significance of the pseudocapsule on MRI of renal neoplasms and its potential application for local staging: a retrospective study. AJR Am J Roentgenol. 2005;184:113–20.
Narumi Y, Miyazaki T, Hatanaka Y, et al. MR imaging evaluation of renal carcinoma. Abdom Imaging. 1997;22:216–25.
Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203–5.
Hui GC, Tuncali K, Tatli S, Morrison PR, Silverman SG. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol. 2008;19:1311–20.
Cornelis F, Balageas P, Le Bras Y, Rigou G, Boutault JR, Bouzgarrou M, Grenier N. Radiologically-guided thermal ablation of renal tumours. Diagn Interv Imaging. 2012;93:246–61.
Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 2. Lessons learned with ablation of 100 tumors. AJR. 2005;185:72–80.
Mylona S, Kokkinaki A, Pomoni M, Galani P, Ntai S, Thanos L. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with solitary kidney: 6 years experience. Eur J Radiol. 2009;69:351–6.
Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR. 2007;189:429–36.
Veltri A, Grosso M, Castagneri F, Garetto I, Sacchetto P, Tosetti I, et al. Radiofrequency thermal ablation of small tumors in transplanted kidneys: an evolving nephron-sparing option. J Vasc Interv Radiol. 2009;20:674–9.
Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113:2671–80.
Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–9.
Rais-Bahrami S, Pietryga JA, Nix JW. Contemporary role of advanced imaging for bladder cancer staging. Urol Oncol. 2016;34:124–33.
Purysko AS, Leão Filho HM, Herts BR. Radiologic imaging of patients with bladder cancer. Semin Oncol. 2012;39:543–58.
Datta SN, Allen GM, Evans R, Vaughton KC, Lucas MG. Urinary tract ultrasonography in the evaluation of haematuria – a report of over 1,000 cases. Ann R Coll Surg Engl. 2002;84:203–5.
Roy C. Tumour pathology of the bladder: the role of MRI. Diagn Interv Imaging. 2012;93:297–309.
Totaro A, Pinto F, Brescia A, Racioppi M, Cappa E, D’Agostino D, Volpe A, Sacco E, Palermo G, Valentini A, Bassi P. Imaging in bladder cancer: present role and future perspectives. Urol Int. 2010;85:373–80.
Kocakoc E, Kiris A, Orhan I, Poyraz AK, Artas H, Firdolas F. Detection of bladder tumors with 3-dimensional sonography and virtual sonographic cystoscopy. J Ultrasound Med. 2008;27:45–53.
Nicolau C, Bunesch L, Sebastia C, Salvador R. Diagnosis of bladder cancer: contrast-enhanced ultrasound. Abdom Imaging. 2010;35:494–503.
ACR Appropriateness Criteria. Hematuria. American College of Radiology. 2008. Accessed www.acr.org
M R. Tumours of the bladder: what does the urologist expect from imaging? Diagn Interv Imaging. 2012;93:291–6.
Sadow CA, Silverman SG, O’Leary MP, JE S. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology. 2008;249:195–202.
Kim JK, Park SY, Ahn HJ, Kim CS, KS C. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology. 2004;231:725–31.
Turkbey B, Basaran C, Karcaaltincaba M, Akpinar E, Oguz B, Akata D, Ozmen MN, O A. Peritoneal carcinomatosis in urinary bladder cancer. Clin Imaging. 2008;32:192–5.
Caoili EM, Cohan RH, Inampudi P, Ellis JH, Shah RB, Faerber GJ, Montie JE. MDCT urography of upper tract urothelial neoplasms. AJR Am J Roentgenol. 2005;184:1873–81.
Pfister C, Roupret M, Wallerand H, Davin JL, Quintens H, Guy L, et al. Recommandations en onco-urologie 2010: tumeurs urothéliales. Prog Urol. 2010;20:S255–74.
Turney BW, Willatt JM, Nixon D, Crew JP, Cowan NC. Computed tomography urography for diagnosing bladder cancer. BJU Int. 2006;98:345–8.
Zhang J, Gerst S, Lefkowitz RA, Bach A. Imaging of bladder cancer. Radiol Clin North Am. 2007;45:183–205.
Tuncbilek N, Kaplan M, Altaner S, Atakan IH, Süt N, Inci O, et al. Value of dynamic contrast enhanced MRI and correlation with tumor angiogenesis in bladder cancer. AJR. 2009;192:949–55.
Scattoni V, Da Pozzo LF, Colombo R. Dynamic gadolinium enhanced magnetic resonance imaging in staging of superficial bladder cancer. J Urol. 1996;155:1594–5.
Abou-El-Ghar ME, El-Assmy A, Refaie HF, El-Diasty T. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology. 2009;251:415–21.
Dağgülli M, Onur MR, Fırdolaş F, Onur R, Kocakoç E, Orhan İ. Role of diffusion MRI and apparent diffusion coefficient measurement in the diagnosis, staging and pathological classification of bladder tumors. Urol Int. 2011;87:346–52.
Takeuchi M, Sasaki S, Ito M, Okada S, Takahashi S, Tatsuya K, et al. Diffusion weighted MR imaging – accuracy for diagnosing t stage and estimating histologic grade. Radiology. 2009;251:112–21.
El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol. 2009;19:1575–81.
Barentsz JO, Ruijs SH, Strijk SP. The role of MR imaging in carcinoma of the urinary bladder. AJR Am J Roentgenol. 1993;160:937–47.
ACR Appropriateness Criteria. Pretreatment staging of invasive bladder cancer. American College of Radiology. 2009. Accessed www.acr.org
Bindu NS, Nagaraj SH, Dushyant VS. State of the art cross-sectional imaging in bladder cancer. Curr Probl Diagn Radiol. 2007;36:83–96.
Tachibana M, Baba S, Deguchi N, et al. Efficacy of gadolinium-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging for differentiation between superficial and muscle-invasive tumor of the bladder: a comparative study with computerized tomography and transurethral ultrasonography. J Urol. 1991;145:1169–73.
Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology. 1994;193:239–45.
Tanimoto A, Yuasa Y, Imai Y, et al. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT. Radiology. 1992;185:741–7.
Swinnen G, Maes A, Pottel H, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641–7.
American Urological Association. Bladder Cancer Clinical Guideline Update Panel. The management of bladder cancer: diagnosis and treatment recommendations. American Urological Association Education and Research, Inc; 2007 (reviewed and validity confirmed 2010). Accessed www.auanet.org
Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186:2158–67.
Beyersdorff D, Zhang J, Schöder H, Bochner B, Hricak H. Bladder cancer: can imaging change patient management? Curr Opin Urol. 2008;18:98–104.
Yoshida S, Koga F, Kawakami S, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology. 2010;75:387–91.
Tabatabaei S, Saylor PJ, Coen J, Dahl DM. Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to know. AJR Am J Roentgenol. 2011;196:1263–6.
Mertan FV, Greer MD, Shih JH, George AK, Kongnyuy M, Muthigi A, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. J Urol. 2016;196:690–6.
Dyke CH, Toi A, Sweet JM. Value of random ultrasound-guided transrectal prostate biopsy. Radiology. 1990;176:345–9.
Ghai STA. Role of transrectal ultrasonography in prostate cancer. Radiol Clin North Am. 2012;50:1061–73.
Volkin D, Turkbey B, Hoang AN, et al. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int. 2014;114:E43–9.
Nevoux P, Ouzzane A, Ahmed HU, et al. Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int. 2012;110:517–23.
Marko J, Gould CF, Bonavia GH, Wolfman DJ. State-of-the-art imaging of prostate cancer. Urol Oncol. 2016;34:134–46.
Brown AM, Elbuluk O, Mertan F, Sankineni S, Margolis DJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B. Recent advances in image-guided targeted prostate biopsy. Abdom Imaging. 2015;40:1788–99.
Barr RG. Elastography in clinical practice. Radiol Clin North Am. 2014;52:1145.
Correas J, Tissier A, Khairoune A, et al. Prostate cancer: diagnostic performance of real-time shear-wave elastography. Radiology. 2015;275:280–9.
Pallwein L, Mitterberger M, Pelzer A, Bartsch G, Strasser H, Pinggera GM, Aigner F, Gradl J, Zur Nedden D, Frauscher F. Ultrasound of prostate cancer: recent advances. Eur Radiol. 2008;18:707–15.
Halpern EJ, Frauscher F, Rosenberg M, Gomella LG. Directed biopsy during contrast-enhanced sonography of the prostate. AJR Am J Roentgenol. 2002;178:915–9.
Pinto PA, Chung PH, Rastinehad Ardeshir R, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol. 2011;186:1281–5.
Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313:390–7.
Vourganti S, Rastinehad A, Yerram NK, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188:2152–7.
Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int. 2014:316272.
Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology. 2011;258:488–95.
Berman RM, Brown AM, Chang SD, Sankineni S, Kadakia M, Wood BJ, Pinto PA, Choyke PL, Turkbey B. DCE MRI of prostate cancer. Abdom Radiol (NY). 2016;41:844–53.
Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol. 2006;176:2432–7.
Lemaitre L, Puech P, Poncelet E, Bouye S, Leroy X, Biserte J, et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol. 2009;19:470–80.
Puech P, Potiron E, Lemaitre L, Leroy X, Haber GP, Crouzet S, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology. 2009;74:1094–9.
Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberatore M, Zerbib M, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011;107:1411–8.
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol. 2016;69:16–40.
Torricelli P, Barberini A, Cinquantini F, Sighinolfi M, Cesinaro AM. 3-T MRI with phased-array coil in local staging of prostatic cancer. Acad Radiol. 2008;15:1118–25.
Lourenco AP, Donegan L, Khalil H, Mainiero MB. Improving outcomes of screening breast MRI with practice evolution: initial clinical experience with 3T compared to 1.5T. J Magn Reson Imaging. 2014;39:535–9.
Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol. 2003;170:S69–75.
Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 2007;244:797–806.
Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection – a multireader study. Radiology. 2009;250:145–51.
Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer. 1994;73:678–87.
Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, Choyke PL, Harisinghani M. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol. 2012;198:1277–88.
Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast- enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005;22:639–46.
Verma S, Rajesh A. A clinically relevant approach to imaging prostate cancer: review. AJR Am J Roentgenol. 2011;196(3 Suppl):S1–10; Quiz S11–4.
Bloch BN, Furman-Haran E, Helbich TH, Lenkinski RE, Degani H, Kratzik C, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging – initial results. Radiology. 2007;245:176–85.
Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996;198:795–805.
Junker D, Quentin M, Nagele U, et al. Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step- section analysis. World J Urol. 2015;33:1023–30.
Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging. 2011;33:167–72.
de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol. 2014;202:343–51.
Ouzzane A, Puech P, Lemaitre L, et al. Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. Urology. 2011;78:1356–62.
Villeirs GM, De Meerleer GO, DeVisschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol. 2011;77:340–5.
Akin O, Hricak H. Imaging of prostate cancer. Radiol Clin North Am. 2007;45:207–22.
George AK, Pinto PA, Rais-Bahrami S. Multiparametric MRI in the PSA screening era. Biomed Res Int. 2014;2014:465816.
George AK, Turkbey B, Valayil SG, Muthigi A, Mertan F, Kongnyuy M, Pinto PA. A urologist’s perspective on prostate cancer imaging: past, present, and future. Abdom Radiol (NY). 2016;41:805–16.
Boonsirikamchai P, Choi S, Frank SJ, Ma J, Elsayes KM, Kaur H, Choi H. MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics. 2013;33:741–61.
Raskolnikov D, George AK, Rais-Bahrami S, et al. The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. J Urol. 2015;194:105–11.
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–9.
Zhang J, Hricak H, Shukla-Dave A, et al. Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology. 2009;253:425–34.
Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the part in tables. Acta Radiol. 2009;50:562–9.
Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othée BJ, Therasse P, Vande Berg B, Tombal B. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25:3281–7.
Park BH, Jeon HG, Jeong BC, Seo SI, Lee HM, Choi HY, Jeon SS. Influence of magnetic resonance imaging in the decision to preserve or resect neurovascular bundles at robotic assisted laparoscopic radical prostatectomy. J Urol. 2014;192:82–8.
Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011;59:962–77.
Grenabo Bergdahl A, Wilderäng U, Aus G, et al. Role of magnetic resonance imaging in prostate cancer screening: a pilot study within the Goteborg randomised screening trial. Eur Urol. 2016;70:566–73.
Fascelli M, Rais-Bahrami S, Sankineni S, et al. Combined biparametric prostate MRI and prostate specific antigen in the detection of prostate cancer: a validation study in a biopsy naive patient population. Urology. 2016;88:125–34.
Ciccarese C, Santoni M, Massari F, et al. Metabolic alterations in renal and prostate cancer. Curr Drug Metab. 2016;17:150–5.
Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci Transl Med. 2013;14:198ra108.
Kara T, Akata D, Akyol F, Karçaaltıncaba M, Özmen M. The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings. Diagn Interv Radiol. 2011;17:38–43.
Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology. 2001;219:817–21.